Metformin · Riomet

What is Metformin?

Metformin is a biguanide antihyperglycemic agent that lowers basal and postprandial plasma glucose by decreasing hepatic glucose production, decreasing intestinal glucose absorption, and improving insulin sensitivity. Metformin inhibits mitochondrial ATP synthesis, activating AMPK through LKB1 and inhibiting the mTOR pathway. It is studied in type 2 diabetes, metastatic breast cancer, endometrial cancer, and nonalcoholic steatohepatitis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as

Riomet, Glucophage

Drug type

Small molecule

Mechanism

Modulator

Pathways

AMPK activation via LKB1, mTOR inhibition, hepatic glucose production reduction, peripheral glucose uptake

Therapy area

Gastroenterology, Metabolic, Oncology

Developer

Sun Pharmaceutical Industries, Inc.

In trials of

ALT, CELC, GILD, LXRX

FDA status

Approved as Riomet, NDA021591 · FDA label

✅ FDA-approved uses

• Type 2 diabetes mellitus

From the indications section of the FDA label (version of Dec 6, 2018). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Endometrial CancerMetastatic Breast CancerNASH - Nonalcoholic SteatohepatitisType 2 Diabetes Mellitus

Sources

• FDA label (DailyMed)
• FDA label Riomet (2018-12-06), indications
• NCI Thesaurus
• ClinicalTrials.gov NCT03066830
• ClinicalTrials.gov NCT03424005
• ClinicalTrials.gov NCT03675893

Updated Oct 11, 2026.